Filing Flows › Health Care › Palatin Technologies (PTN)
Palatin Technologies (PTN) earnings and revenue breakdown
Latest: Q4 FY26 · 10-K filed Sep 28, 2026 · Palatin Technologies (PTN) Q4 FY26 earnings results →
Palatin Technologies made $301K in Q4 FY26. Operating margin n/m, net loss $4.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Sep 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $301K in Q4 FY26, down 92% from the previous quarter.
Operating costs exceeded revenue by $4.4M, an operating margin of -1469.5%. The quarter ended with a net loss of $4.4M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $17K of depreciation and $431K of share-based compensation. Working capital and other items added $1.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 FY26 | 10-K | Sep 28, 2026 | $301K | — | n/m | −$4.4M | −$2.7M |
| Q3 FY26 | 10-Q | May 13, 2026 | $3.9M | — | -40.3% | −$1.4M | −$4.4M |
| Q2 FY26 | 10-Q | Feb 17, 2026 | $116K | — | n/m | −$7.3M | −$4.8M |
| Q1 FY26 | 10-Q | Nov 14, 2025 | $8.8M | — | 52.8% | $4.7M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Palatin Technologies
Palatin™ is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (“MCR”) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.
In its own words, from its annual report, filed Sep 28, 2026.
Palatin Technologies against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PTN Palatin Technologies | Q4 FY26 | $301K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Palatin Technologies 10-K on SEC EDGAR · CIK 911216 · Pharmaceutical Preparations
13F: who owns PTN and who is buying
More on PTN
History
Every quarter: Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results